FDA Hands Expanded Indication to Gilead’s Vemlidy for Chronic HBV Infection in Pediatric Patients

Phase II clinical study showed that children as young as six years of age with hepatitis B virus could benefit from treatment with Vemlidy.

Source link
#FDA #Hands #Expanded #Indication #Gileads #Vemlidy #Chronic #HBV #Infection #Pediatric #Patients